ARTICLE | Clinical News
Opicinumab: Additional Phase II data
September 26, 2016 7:00 AM UTC
Additional data from the double-blind, international Phase II SYNERGY trial in 412 evaluable patients with relapsing forms of MS, including relapsing-remitting MS (RRMS) and secondary progressive MS (...